# 3/3 COMpAAAS Tripartite: ART-CC, KP, and VA

> **NIH NIH U01** · YALE UNIVERSITY · 2021 · $519,196

## Abstract

Abstract
HIV infected adults who drink alcohol are already physiologically frail due to HIV infection, comorbidity
(including hepatitis C infection), polypharmacy and associated substance use. In this setting, biomedical
consequences of alcohol use can occur at lower risk use and may be unappreciated or misattributed. The
“Consortium to improve OutcoMes in HIV/Aids, Alcohol, Aging & multi-Substance” (COMpAAAS) is supported
by NIH/NIAAA award U24AA020794 to study this issue in a single sample, the Veterans Aging Cohort Study
(VACS). In this set of three applications, the Antiretroviral Therapy Cohort Collaboration (ART-CC) and Kaiser
Permanente (KP) teams join the Veterans Healthcare System (VA) team as COMpAAAS Tripartite: ART-CC,
KP, and VA. Our long term goal is to inform intervention design and implementation. Together we will study
biomedical consequences of alcohol and associated substance use in HIV extending the scope and
generalizability of VACS from a single national healthcare system to 12 systems across 10 North American
and European countries, doubling the HIV+ sample and substantially increasing the diversity of subjects.
Importantly, COMpAAAS Tripartite also extends the pool of uninfected comparators (more women, young
patients, and HCV+) available for analyses, a critical step if we are to understand how alcohol differentially
affects individual biomedical outcomes by HIV status by gender, age, and HCV status. Using propensity and
related methods and variables tailored to each aim and hypothesis, we will closely match HIV+ subjects with
uninfected comparators drawing from 3.7 million KP members (1.9 million women) and 5 million veterans born
in 1945-1965 (Birth Cohort, includes 450,000 HCV+). ART-CC, KP, and VA will also participate in an HIV+
substudy (n=2250), The Medications, Alcohol, Substance use in HIV Study (MASH), involving new,
prospective data on potentially inappropriate medications (PIMS) and direct biomarker measurements for
alcohol and associated substances (tobacco, marijuana, opioids, cocaine, and methamphetamine). ART-CC,
KP and VA have identical aims and protocols and contribute and share data. Aims compare HIV infected and
uninfected individuals and address: 1) attributable risk from alcohol and tobacco for all cause and cause
specific hospitalization and mortality; 2) the impact of alcohol and tobacco on primary and secondary
preventative care; and 3) the role of alcohol and ART on drug interactions (potentially inappropriate
medications) leading to adverse biomedical consequences. VA will coordinate sharing limited data sets based
on the HIV Cohorts Data Exchange Protocol (HICDEP) a standardized format for data sharing. Standardized
methods for data cleaning, imputation, and analyses will be employed.

## Key facts

- **NIH application ID:** 10238904
- **Project number:** 5U01AA026224-05
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** Amy Caroline Justice
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $519,196
- **Award type:** 5
- **Project period:** 2017-09-20 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10238904

## Citation

> US National Institutes of Health, RePORTER application 10238904, 3/3 COMpAAAS Tripartite: ART-CC, KP, and VA (5U01AA026224-05). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10238904. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*